Clinical Trials Browser

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

Neurofibromatosis 1, Neurofibrosarcoma

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Colorectal Neoplasms

Lymphoma, Non-Hodgkin, Neuroblastoma, Central Nervous System Neoplasms

Carcinoma, Non-Small-Cell Lung, Thymoma, Small Cell Lung Carcinoma

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Neurofibromatosis 1, Neurofibroma, Plexiform, Optic Nerve Glioma

Carcinoma, Non-Small-Cell Lung

Non-small Cell Lung Cancer Metastatic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Uveal Melanoma, Melanoma

Carcinoma, Non-Small-Cell Lung

Neoplasm Metastasis

Neurofibromatosis 1

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung, Neoplasms

Cystadenocarcinoma, Serous

Advanced Cancer

Pancreatic Neoplasms

Colonic Neoplasms, Colorectal Neoplasms

Biliary Tract Neoplasms, Breast Neoplasms, Lung Neoplasms, Melanoma, Colorectal Neoplasms, Disease Progression

Endometrial Adenocarcinoma

Breast Neoplasms

Locally Advanced or Metastatic Solid Tumors

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Uveal Melanoma

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Neoplasm Metastasis, Thyroid Diseases, Thyroid Neoplasms

Breast Neoplasms

Thyroid Cancer, Papillary, Thyroid Neoplasms

Uveal Melanoma, Neoplasm Metastasis

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Neoplasms

Solid Tumors

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Bile Duct Neoplasms, Carcinoma, Hepatocellular

Pancreatic Neoplasms

Adult Solid Neoplasm

Adult Solid Neoplasm

Solid Tumours

Clinical Trials

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer

Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies

DOC-MEK

Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

INSPECT

Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC

SAFIR02_Lung

SELECT-2

Intermittent Selumetinib for Uveal Melanoma

Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC

MK-8353-014

Selumetinib Paediatric NF1 Japan Study

Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

MEKRT

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)

Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer

A Study of ARRY-142886 in Patients With Advanced Cancer

Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy

A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)

Selumetinib in Combination With Gefitinib in NSCLC Patients

AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients

SELECT-3

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...

Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244

Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer

Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine

SUMIT

Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer

A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male Volunteers

To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects

ABC-04

Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery

A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers.

Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients

S1115

Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies

Selumetinib in Cancers With BRAF Mutations

To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers

Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery